FLT1 and hepatocellular carcinoma: Being a multi-kinase inhibitor, sorafenib targets the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway, the vascular endothelial growth factor receptors-1/2/3 (VEGFR1/2/3), and c-KIT, among other targets, that provide a median survival advantage of nearly 3 months and reduce the risk of mortality by 31% in patients with an advanced stage of HCC (4).